Renal therapies get disease-specific

Renal diseases are back in pharma pipelines and attracting a level of investment the area hasn’t seen before. A convergence of new biology insights, innovation in endpoints, and clinical success stories is fueling a new era of therapies tailored to specific indications, moving away from development of sledgehammer-type approaches applied broadly across chronic kidney diseases. 

One rare renal disease — IgA nephropathy — is already benefitting from the shift, and biotech executives interviewed by BioCentury expect others to follow, ushering in a wave of disease-modifying approaches...